FDA grants Breakthrough Device Designation for Podascan™ Chronic Wound Diagnostic David KolbMarch 16, 2021
Supernus to Acquire Biscayne Neurotherapeutics - Adds Phase 1 Novel Epilepsy Development Program David KolbSeptember 13, 2018
Significant Supplements Launched Its First Product Utilizing Yale University Technology David KolbJanuary 10, 2018
Significant Supplements Licenses Acid Reflux Technology From Yale University David KolbDecember 12, 2017
Emunamedica Awarded Category III Reimbursement Coding By CPT-AMA Committee David KolbDecember 11, 2017
Partikula Appoints Leading Cancer Metabolism Experts to Advisory Board; Extends Its Work On Its Multiple Checkpoint Inhibitors; Adds Seasoned Technical Development Professional to the Management Team David KolbOctober 13, 2016
Partikula Reports Positive Results From A Multi-Checkpoint Protein Inhibition Study Of Its First-In-Class Precision Tumor Microenvironment Modifiers (TMEM™) David KolbDecember 4, 2015
Biscayne Neurotherapeutics Adding Clinical-Stage Novel Epilepsy Program With Insero Merger David KolbOctober 5, 2015
Partikula Announces $5 Million Series A Funding To Develop Novel First-In-Class Mitochondrial Targeted Therapeutics David KolbFebruary 2, 2015
Chronic Wound Diagnostics Company Emunamedica Announces Receipt of U.S. Patent Allowance David KolbApril 22, 2014
Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-Resistant Epilepsy David KolbMay 17, 2013
Insero Health Closes Initial Round of Financing and Signs Exclusive Licenses With Harvard and Yale David KolbFebruary 2, 2012
Emunamedica licenses technology for near-infrared wound monitor from Drexel University David KolbAugust 19, 2010